STAMFORD, Conn., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at Kidney Week 2017, the American Society of Nephrology's Annual Meeting, to be held October 31 - November 5, 2017 in New Orleans, LA.
Presentations will include clinical data from a recently completed Phase 2b trial of I.V. CR845 in hemodialysis patients suffering from moderate-to-severe pruritus.
Details for the presentations are as follows:
CR845 Oral Presentation:
|Title:||"Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Improving the Quality of Life of Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus"|
Date / Time:||Saturday, November 4, 2017; 4:42 - 4:54 p.m. CT|
|Presenter: ||Frédérique Menzaghi, Ph.D., Senior Vice President, Research and Development, Cara Therapeutics|
CR845 Poster Presentation:
|Poster Title:||"Randomized, Placebo-Controlled Study on the Efficacy of CR845 in
Reducing Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients"|
|Date / Time:||Friday, November 3, 2017; 9:30 a.m. - 2:30 p.m. CT|
|Presenter:||Robert Spencer, Ph.D., Senior Director, Research and Development, Cara Therapeutics|
|Title:||"Pioneering a Novel Approach to Relieve CKD-Associated Pruritus: Targeting Peripheral Kappa Opioid Receptors"|
|Date / Time:||Thursday, November 2, 2017; 10:00 - 11:00 a.m. CT|
|Moderator:||Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics|
Faculty:||James A. Tumlin, M.D., F.A.S.N., Director & Chief Medical Officer, NephroNet, Clinical Trials Consortium; Founder & Medical Director, Southeast Renal Research Institute; Professor, Division of Nephrology, University of Tennessee College of Medicine|
For more information about Kidney Week 2017, visit https://www.asn-online.org/education/kidneyweek/.
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects
typically associated with currently available opioid pain therapeutics.
Stern Investor Relations, Inc.
Source: Cara Therapeutics, Inc.
News Provided by Acquire Media